CytomX Therapeutics Inc. (CTMX)
$3.67
$0.31
(9.23%)
As on 01-Sep-2026 16:28EDT
Market cap
$699 Mln
Revenue (TTM)
$18 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
24.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
217,899,284
10 Years Aggregate
CFO
$-323.87 Mln
EBITDA
$-576.16 Mln
Net Profit
$-565.93 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CytomX Therapeutics (CTMX)
| -13.8 | 18.4 | 1.9 | 79.9 | 34.7 | -6.4 | -11.0 |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
CytomX Therapeutics (CTMX)
| 313.6 | -33.3 | -3.1 | -63.0 | -33.9 | -21.2 | -45.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CytomX Therapeutics (CTMX)
|
3.7 | 699.5 | 18.3 | -79.7 | -434.0 | -39.7 | -- | 2.5 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout CytomX Therapeutics (CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology... biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California. Read more
-
Chairman & CEO
Dr. Sean A. McCarthy DPHIL
-
Chairman & CEO
Dr. Sean A. McCarthy DPHIL
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for CytomX Therapeutics (CTMX)
What is the current share price of CytomX Therapeutics Inc (CTMX) Today?
The share price of CytomX Therapeutics Inc (CTMX) is $3.67 (NASDAQ) as of 01-Sep-2026 16:28 EDT. CytomX Therapeutics Inc (CTMX) has given a return of 34.75% in the last 3 years.
What is the current PB & PE ratio of CytomX Therapeutics Inc (CTMX)?
Since, TTM earnings of CytomX Therapeutics Inc (CTMX) is negative, P/E ratio is not available.
The P/B ratio of CytomX Therapeutics Inc (CTMX) is 2.47 times as on 28-Aug-2026, a 52 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-41.74 |
7.32 |
2024 |
2.59 |
-180.93 |
2023 |
-183.36 |
-2.20 |
2022 |
-1.09 |
-1.24 |
2021 |
-3.50 |
3.16 |
What is the 52 Week High and Low of CytomX Therapeutics Inc (CTMX)?
The 52-week high and low of CytomX Therapeutics Inc (CTMX) are Rs 8.21 and Rs 1.90 as of 02-Sep-2026.
What is the market cap of CytomX Therapeutics Inc (CTMX)?
CytomX Therapeutics Inc (CTMX) has a market capitalisation of $ 699 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in CytomX Therapeutics Inc (CTMX)?
Before investing in CytomX Therapeutics Inc (CTMX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.